NCT06000514View on ClinicalTrials.gov

Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 17, 2019

Primary Completion Date

April 6, 2022

Study Completion Date

July 7, 2022

Conditions
Cutaneous Leishmaniasis, American
Interventions
DRUG

Sm29 Protein, Schistosoma Mansoni

Sm29 cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.

DRUG

Pentavalent antimony (Sbv)

Placebo cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.

Trial Locations (1)

40000

Corte de Pedra Health Post, Presidente Tancredo Neves

All Listed Sponsors
collaborator

Conselho Nacional de Desenvolvimento Científico e Tecnológico

OTHER_GOV

collaborator

Oswaldo Cruz Foundation

OTHER

lead

Hospital Universitário Professor Edgard Santos

OTHER

NCT06000514 - Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis. | Biotech Hunter | Biotech Hunter